161 related articles for article (PubMed ID: 15622331)
1. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Madelaine J; Cadranel J; Zalcman G
Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
[No Abstract] [Full Text] [Related]
2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
[No Abstract] [Full Text] [Related]
4. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG; Jänne PA; Lee JC; Tracy S; Greulich H; Gabriel S; Herman P; Kaye FJ; Lindeman N; Boggon TJ; Naoki K; Sasaki H; Fujii Y; Eck MJ; Sellers WR; Johnson BE; Meyerson M
Science; 2004 Jun; 304(5676):1497-500. PubMed ID: 15118125
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Price N; Belani C
Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
[No Abstract] [Full Text] [Related]
6. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
7. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
8. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
9. Targeting targeted therapy.
Green MR
N Engl J Med; 2004 May; 350(21):2191-3. PubMed ID: 15118072
[No Abstract] [Full Text] [Related]
10. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.
Hirano S; Sano K; Takeda Y; Ishii S; Naka G; Iikura M; Izumi S; Hojo M; Sugiyama H; Kobayashi N; Kudo K
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1501-6. PubMed ID: 23064060
[TBL] [Abstract][Full Text] [Related]
12. Response to gefitinib in pericardial effusion due to lung cancer.
Kikuchi N; Satoh H; Kodama T; Haraguchi N; Sekizawa K
Acta Medica (Hradec Kralove); 2003; 46(4):215-6. PubMed ID: 14965177
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
[TBL] [Abstract][Full Text] [Related]
14. ERBB2 kinase mutations in lung-cancer tumours.
Senior K
Lancet Oncol; 2004 Nov; 5(11):647. PubMed ID: 15536687
[No Abstract] [Full Text] [Related]
15. Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
Chou WC; Huang SF; Yeh KY; Wang HM; Liu MY; Hsieh JJ; Cheung YC; Chang JW
Jpn J Clin Oncol; 2006 Aug; 36(8):523-6. PubMed ID: 16803841
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.
Lai SW; Ho CL; Dai MS; Chen WL; Chang PY; Wu YY; Perng CL; Lai CY
J BUON; 2014; 19(2):459-65. PubMed ID: 24965407
[TBL] [Abstract][Full Text] [Related]
17. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
18. Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
Yang TY; Tsai CR; Chen KC; Hsu KH; Lee HM; Chang GC
J Clin Oncol; 2011 Jun; 29(16):e468-9. PubMed ID: 21422421
[No Abstract] [Full Text] [Related]
19. [Gefitinib and epidermal growth factor receptor gene mutation].
Fukui T; Mitsudomi T
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1168-72. PubMed ID: 17687196
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
